Charles Russell Speechlys advises BGF on its investment in Virtual1
Charles Russell Speechlys has advised BGF (Business Growth Fund) on its investment in Virtual1, a London-based cloud and connectivity service provider.
Virtual1 delivers cloud and connectivity services exclusively to the wholesale market, aggregating its own cutting edge London-based network with networks from other carriers onto a single scalable platform. Founded in 2007 by CEO Tom O’Hagan, Virtual1 featured in the Sunday Times Tech Track 100 for three consecutive years and generated revenue close to £18m in 2015/16. BGF is the UK’s most active provider of growth capital in small and mid-sized businesses, having invested more than £1bn in over 140 companies since 2011.
Chris Hodges of BGF commented:
“We are really excited about our investment in Virtual1 and supporting the company’s ambitions. The team at CRS helped make this possible by providing BGF with robust legal support, as always backed-up by pragmatic, commercial thinking.”
The Charles Russell Speechlys core team comprised Head of Private Equity Malcolm MacDougall, Private Equity Associates Amy Utley and Olivia Mackie, Real Estate Associate Raza Anjum and Tax Associate Helen Coward, with support from members of the Commercial and Employment teams.
Malcolm MacDougall commented:
“We are delighted to have completed our fifth transaction for BGF and to have assisted in this investment to enable Virtual1 to invest in additional network infrastructure and support its long-term growth plans. Once again it was a pleasure working with the BGF team on the deal.”
For more information, please contact, Malcolm MacDougall, Head of Private Equity on +44 (0)20 7427 4544 or email@example.com
News & Insights
It's About Time!
The industry’s holy trinity of time, cost and quality is well known and yet unlocking the treatment of delay remains a continual challenge.
Charles Russell Speechlys advises Kreos and SVB on £20m growth capital investment to Mereo BioPharma
We advised Kreos Capital and Silicon Valley Bank on the refinancing of £20 million growth capital investment to Mereo BioPharma Group